![Jean Fan](data:image/svg+xml,<svg xmlns="http://www.w3.org/2000/svg" width="16" height="16" fill="%231b1b1b" class="bi bi-person-fill" viewBox="0 0 16 16"><path d="M3 14s-1 0-1-1 1-4 6-4 6 3 6 4-1 1-1 1zm5-6a3 3 0 1 0 0-6 3 3 0 0 0 0 6"/></svg>)
Jean Fan
Directeur Technique/Scientifique/R&D chez
NEOIMMUNETECH, INC.
Profil
Jean Fan currently works at TransThera Sciences (Nanjing), Inc., as Chief Medical Officer from 2022 and NeoImmuneTech, Inc., as Chief Clinical Officer from 2021.
Dr. Fan also formerly worked at Blueprint Medicines Corp., as Vice President-Clinical Development.
Postes actifs de Jean Fan
| Sociétés | Poste | Début |
|---|---|---|
| NEOIMMUNETECH, INC. | Directeur Technique/Scientifique/R&D | 01/01/2020 |
| TRANSTHERA SCIENCES (NANJING), INC. | Directeur Technique/Scientifique/R&D | 01/11/2022 |
Anciens postes connus de Jean Fan
| Sociétés | Poste | Fin |
|---|---|---|
| BLUEPRINT MEDICINES CORPORATION | Directeur Technique/Scientifique/R&D | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
1
Relations au 1er degré
3
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Blueprint Medicines Corp.
 Blueprint Medicines Corp. BiotechnologyHealth Technology Develops cancer therapies that harness the growing understanding of the molecular blueprint of cancer | Health Technology |
NeoImmuneTech, Inc.
 NeoImmuneTech, Inc. BiotechnologyHealth Technology Develops novel immuno-therapeutics | Health Technology |
TransThera Sciences (Nanjing), Inc.
 TransThera Sciences (Nanjing), Inc. BiotechnologyHealth Technology Operates as a biopharmaceutical company focusing on discovering and developing small molecule therapies | Health Technology |
